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TheMYConcoproteins are thought to stimulate tumor
cell growth and proliferation through amplification of
gene transcription, a mechanism that has thwarted
most efforts to inhibit MYC function as potential
cancer therapy. Using a covalent inhibitor of cyclin-
dependent kinase 7 (CDK7) to disrupt the transcrip-
tion of amplified MYCN in neuroblastoma cells,
we demonstrate downregulation of the oncoprotein
with consequent massive suppression of MYCN-
driven global transcriptional amplification. This res-
ponse translated to significant tumor regression in a
mouse model of high-risk neuroblastoma, without
the introduction of systemic toxicity. The striking
treatment selectivity of MYCN-overexpressing cells
correlated with preferential downregulation of su-
per-enhancer-associated genes, including MYCN
and other known oncogenic drivers in neuroblas-
toma. These results indicate that CDK7 inhibition, by
selectively targeting the mechanisms that promote
global transcriptional amplification in tumor cells,
may be useful therapy for cancers that are driven by
MYC family oncoproteins.
INTRODUCTION
Many human cancers depend on the deregulated expression of
MYC family members for their aberrant growth and proliferation,
with elevated expression of these oncogenes predicting aggres-
sive disease and a poor clinical outcome (Eilers and Eisenman,
2008; Wasylishen and Penn, 2010). Deactivation of MYC in cell
lines and MYC-induced transgenic tumors causes proliferative1126 Cell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc.arrest and tumor regression (Arvanitis and Felsher, 2006; Soucek
et al., 2008), suggesting that effective targeting of MYC proteins
would have broad therapeutic benefit. Recently, several groups
reported that oncogenic MYC elicits its plethora of downstream
effects in tumor cells through global transcriptional amplification,
leading tomassively upregulated expression of genes involved in
multiple processes (Lin et al., 2012; Love´n et al., 2012; Nie et al.,
2012; Schuhmacher and Eick, 2013). When present at physio-
logical levels, MYC binds to the core promoters of actively
transcribed genes; however, in tumor cells with MYC overex-
pression, increased MYC levels are observed at both the core
promoters and enhancers of the same set of genes, resulting
in increased levels of transcripts per cell. This mechanism pro-
vides an explanation for the lack of a common MYC transcrip-
tional signature and for the diverse effects of deregulated MYC
in cancer cells. Another general feature of deregulated MYC is
its transcriptional regulation by super-enhancers (SEs), clusters
of enhancers that are densely occupied by transcription factors,
cofactors, and chromatin regulators (Hnisz et al., 2013). SEs
are acquired by cancer cells through gene amplification, trans-
location or transcription factor overexpression. They facilitate
high-level expression of genes, including MYC, whose protein
products are critical for the control of cell identity, growth, and
proliferation, and which are especially sensitive to perturbation
(Chapuy et al., 2013; Hnisz et al., 2013; Love´n et al., 2013). These
emerging insights into the role of oncogenicMYC as an SE-asso-
ciated transcriptional amplifier suggest that strategies aimed
at disrupting the molecular mechanisms that drive this function
might provide useful therapy for different MYC-dependent
tumors.
The transcription cycle of RNA polymerase II (Pol II) is regu-
lated by a set of cyclin-dependent kinases (CDKs) that have crit-
ical roles in transcription initiation and elongation (Larochelle
et al., 2012). In contrast to the cell-cycle CDKs which are largely
responsible for cell-cycle transition, these transcriptional CDKs
(especially CDK7, a subunit of TFIIH, and CDK9, a subunit of
pTEFb) phosphorylate the carboxy-terminal domain (CTD) of
Pol II, facilitating efficient transcriptional initiation, pause release
and elongation. Moreover, most CDKs are activated through
T-loop phosphorylation by a CDK-activating kinase (CAK), which
in metazoans appears to be uniquely controlled by CDK7 (Fisher
and Morgan, 1994; Glover-Cutter et al., 2009; Larochelle et al.,
2007, 2012; Rossignol et al., 1997; Serizawa et al., 1995). Inhibi-
tion of transcriptional CDKs primarily affects the accumulation of
transcripts with short half-lives, including antiapoptosis family
members and cell-cycle regulators (Garriga and Gran˜a, 2004;
Lam et al., 2001), rendering this group of kinases ideal candi-
dates for blockingMYC-dependent transcriptional amplification.
Here, we investigate whether inhibition of transcriptional CDKs
can be exploited to disrupt aberrant MYC-driven transcription,
using the deregulated expression of MYCN as a model. The
MYCN protein shares most of the physical properties of MYC
(Kohl et al., 1986) and is considered functionally interchange-
able, based on the similarity of their transcriptional programs,
the cellular phenotypes they induce, and the ability of MYCN to
replaceMYC during murine development (Boon et al., 2001; Ma-
lynn et al., 2000; Toyoshima et al., 2012). In neuroblastoma (NB),
a pediatric solid tumor arising in the peripheral sympathetic ner-
vous system, MYCN amplification is typically associated with a
dismal prognosis, regardless of the treatment used (Brodeur
et al., 1984; Seeger et al., 1985).
We demonstrate that THZ1, a newly developed covalent
inhibitor of CDK7 (Kwiatkowski et al., 2014), selectively targets
MYCN-amplified NB cells, leading to global repression of
MYCN-dependent transcriptional amplification. This response
induces sustained growth inhibition of tumors in a mouse model
of NB. The remarkable sensitivity of MYCN-amplified cells to
CDK7 inhibition is associated with preferentially reduced expres-
sion of SE-associated oncogenic drivers, especially MYCN.
RESULTS
THZ1 Exerts Potent and Selective Effects in
MYC-Deregulated Cells
To identify CDKs whose depletion might lead to decreased
MYCN expression and subsequent apoptosis, we performed a
short hairpin (shRNA) knockdown screen of CDKs with known
transcriptional activities (CDK7, CDK8, CDK9, CDK12, CDK13,
and CDK19) in Kelly cells, a human NB line that expresses very
high levels ofMYCN RNA and protein due to genomically ampli-
fied MYCN (100–120 copies per cell) (Schwab et al., 1983). Ge-
netic depletion of CDK7, CDK8, CDK9, or CDK19 led to marked
decreases of MYCN RNA and protein with a concomitant in-
crease in cleaved caspase 3 (CC3) expression (Figures S1A
andS1B available online). To reproduce these results pharmaco-
logically, we tested a panel of 11 inhibitors with activity against
transcriptional CDKs in three MYCN-amplified cell lines,
observing a range of sensitivities, with the highest potency
(IC50, 6–9 nM) shown by a newly developed covalent phenylami-
nopyrimidine inhibitor of CDK7, THZ1 (Kwiatkowski et al., 2014)
(Figure S1C; Table S1). Similar results were obtained when THZ1
was tested against a larger panel of MYCN-amplified NB cell
lines with varying levels of MYCN expression (Figures 1A andCS1D). Importantly, NB cells without MYCN amplification were
far less sensitive to THZ1, with IC50 values averaging ten times
higher than those of MYCN-amplified cells (Figure 1A; Table
S1). Notably, the NBL-S cell line, which expresses high levels
ofMYCN without genomic amplification (Cohn et al., 1990) (Fig-
ure S1D), was quite sensitive to THZ1, while two nontransformed
lines (B6-MEFs and NIH 3T3) were relatively insensitive (Fig-
ure 1A).MYCN-amplified cells also showed enhanced sensitivity
to THZ1R, a reversible analog of THZ1 that lacks the acrylamide
moiety required for covalent bond formation, although it was not
as potent as the covalent inhibitor (Figure 1B). The strong selec-
tivity of THZ1 forMYCN-amplified cells was not restricted to NB,
but extended to H262-BT111, a human primitive neuroectoder-
mal tumor cell line expressing amplified MYCN (K. Ligon, per-
sonal communication) and Raji and Daudi lymphoma cells,
both characterized byMYC overexpression due to chromosomal
translocation (Nishikura et al., 1985; Veronese et al., 1995) (Fig-
ure S1E). To probe this preferential effect further, we tested the
extent of target engagement in NB cells, using a biotinylated de-
rivative of THZ1 (bio-THZ1) with or without THZ1 pretreatment.
Bio-THZ1 consistently bound to CDK7 in both MYCN-amplified
and nonamplified untreated cells (Figure S1F), but became less
efficient after THZ1 treatment, suggesting that target recognition
was not a major factor in the enhanced inhibitory effects of THZ1
in MYCN-amplified cells.
Next, we studied the growth inhibitory effects of THZ1.MYCN-
amplified cells treated with THZ1 underwent cell-cycle arrest in
G2/M at 24 hr, an effect that was not observed inMYCN-nonam-
plified NB cells, even after 48 hr (Figure 1C). Moreover, THZ1 led
to a profound induction of apoptosis in high MYCN-expressing
cells, but not in cells expressing nonamplified MYCN (Figures
1D and S1G). Together, these data indicate that THZ1 induces
selective cytotoxicity not only in NB cells with MYCN amplifica-
tion, but also in other cancers overexpressing either the MYCN
or MYC oncogene.
THZ1 Inhibits Tumor Growth in aMouseModel of Human
MYCN-Amplified NB
Given the relative lack of target specificity of past CDK inhibitors,
leading to adverse effects in normal cells (Lapenna and Gior-
dano, 2009), we assessed the tolerability of THZ1 in non-tu-
mor-bearing mice (n = 6) treated with 10 mg/kg intravenously
twice daily. No systemic toxicity was observed even after
4 weeks of continuous administration (data not shown). We
next tested the therapeutic effects of THZ1 in xenograft models
ofMYCN-amplified human NB derived from subcutaneous flank
injection of Kelly cells. When tumors reached an optimal size
(mean volume, 150 mm3; range, 75–235 mm3), the animals
were divided into two groups and treated with vehicle (n = 9) or
THZ1 as above (n = 14). Treatment was continued for a mean
of 20 days (range, 15–24 days) in the control group and
24 days (range, 20–28 days) in the THZ1 group. Mice receiving
THZ1 had a statistically significant reduction in tumor growth,
again without toxicity (Figure 1E). Two animals remained free
of tumor recurrence at 35 and 128 days posttreatment.
Tumors from vehicle-treated mice displayed histological fea-
tures of human NB with poorly differentiated, small round blue
cells displaying high mitotic activity (Figure 1F). By contrast,ell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc. 1127
Figure 1. THZ1 Exhibits High Potency and Selectivity against MYCN-Amplified Tumor Cells
(A) Dose-response curves ofMYCN-amplified and nonamplified human NB and murine fibroblast cells after treatment with increasing concentrations of THZ1 for
72 hr. Percent cell viability relative to that of DMSO-treated cells is shown here and in (B). Data represent mean ± SD of three replicates here and in (B).
(B) Dose-response curves of NB cells treated as in (A) with the reversible CDK7 inhibitor THZ1R.
(C) Cell-cycle analysis ofMYCN-amplified versus nonamplified NB cells exposed to THZ1 (100 nM 3 24 and 48 hr) by flow cytometry with propidium iodide (PI)
staining. Results are representative of three replicates. The scale and axes are indicated in the lower left corner.
(D) Apoptosis analysis inMYCN-amplified and nonamplifiedNB cells treatedwith THZ1 as in (C) by flow cytometry with Annexin V staining. Data represent mean ±
SD of three replicates. ***p < 0.0001, **p < 0.001 (Student’s t test).
(E) Tumor volumes ofMYCN-amplified humanNB xenografts in NU/NU (Crl:NU-Foxn1nu)mice treated with THZ1 (10mg/kg intravenously [i.v.] twice daily) (n = 14)
or vehicle (n = 9) for 28 days. Mean ± SD values are presented. ***p < 0.001; **p < 0.01; *p < 0.05 (multiple t test, Holm-Sidak method).
(F) Immunohistochemical (IHC) analysis of morphology (hematoxylin & eosin [H&E]), proliferation (Ki67) and apoptosis (cleaved caspase 3 [CC3]) in tumors
harvested from animals treated with vehicle or THZ1 as in (E) for 12 days. Scale bar represents 25 mM.
See also Figure S1 and Table S1.
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Figure 2. THZ1 Inhibits General Transcription and Cell-Cycle Regulation in MYCN-Amplified Tumor Models
(A) Immunoblot analysis of RNA Pol II CTD phosphorylation in MYCN-amplified and nonamplified NB cells treated with DMSO or THZ1 at the indicated con-
centrations for the indicated times.
(B) Immunoblot analysis of RNA Pol II CTD phosphorylation in human NB xenograft tumor cells obtained from mice treated with vehicle or THZ1 (10 mg/kg i.v.
twice daily) for 12 days.
(C) Immunoblot analysis of MCL1 in MYCN-amplified (Kelly, NGP) versus nonamplified (SK-N-FI, SH-SY5Y) NB cells following treatment with THZ1 at the
indicated concentrations and durations.
(D) Immunoblot analysis of proteins involved in cell-cycle progression in MYCN-amplified (Kelly, IMR-32) and nonamplified (SH-SY5Y) NB cells following
treatment with THZ1 100 nM for 3 and 6 hr.
See also Figure S2.the vast majority of tumor cells in the THZ1-treated animals
demonstrated necrosis, reduced proliferative activity and
increased apoptosis. To ensure target engagement in the tumor
cells, we used bio-THZ1 to pull down CDK7 in cell lysates from
both vehicle- and THZ1-treated animals, noting decreased bind-
ing with bio-THZ1 in the latter (Figure S1H). We also confirmed
that the lack of toxicity in the animal models did not reflect
THZ1 selectivity for human CDK7, as bio-THZ1 formed a com-
plex with murine CDK7 in cell lysates from NIH 3T3 cells treated
with THZ1 (Figure S1H). These results demonstrate the feasibility
of specifically targeting CDK7 in tumor cells driven by deregu-
lated MYC or MYCN.
THZ1 Affects Both Transcription and Cell-Cycle
Progression in MYCN-Amplified Cells
As a transcriptional kinase, CDK7 exerts its effects through regu-
lation of RNA Pol II-mediated transcriptional initiation and pause
establishment, while also affecting elongation through its CAK
activity on other transcriptional CDKs (Glover-Cutter et al.,
2009; Larochelle et al., 2012; Palancade and Bensaude, 2003).
We observed a dose-dependent decrease in the initiation-asso-
ciated serine 5 (S5) and serine 7 (S7) and the elongation-associ-
ated serine 2 (S2) Pol II phosphorylation in MYCN-amplified but
not nonamplified cells treated with THZ1 (Figures 2A and S2A).CPol II CTD phosphorylation was also downregulated in tumor
cells from animals treated with THZ1 (Figure 2B). Downregula-
tion of CDK7 phosphorylation was seen inMYCN-amplified cells
(Figure S2B), consistent with the finding that CDK7 is regulated
by phosphorylation within its own activation (T) loop (Larochelle
et al., 2012). Phosphorylation of CDK9 was also decreased in
MYCN-amplified cells (Figure S2C), reinforcing the effect of
THZ1 on transcription elongation. Total protein levels of CDK9
were also decreased in these cells but not nonamplified cells,
suggesting that THZ1-induced CDK7 inhibition might also target
the transcription of CDK9 (Figure S2C).
The decrease in Pol II phosphorylation after THZ1 treatment in
MYCN-amplified cells coincided with the loss of the short-lived
antiapoptotic protein MCL1 (Figure 2C). Similar effects on Pol II
CTD phosphorylation and MCL1 levels were observed in Raji,
Daudi, and H262-BTIII cells, all of which depend on MYC or
MYCN overexpression and are sensitive to THZ1 (Figure S2D).
Importantly, the effects of THZ1, including Pol II CTD phosphor-
ylation and the induction of apoptosis, could be rescued by a
mutation in the covalent binding site of CDK7 (CDK7C312S) (Fig-
ure S2E), indicating on-target effects of THZ1 on CDK7.
CDK7 also stimulates cell-cycle progression by activating
CDK1 and CDK2 through its T-loop phosphorylation function
(Larochelle et al., 2007). We observed a time-dependentell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc. 1129
Figure 3. THZ1 Causes Massive Downregulation of Actively Transcribed Genes in MYCN-Overexpressing NB Cells
(A) Heatmap of gene expression values in MYCN-amplified and nonamplified cells treated with THZ1 (100 nM for 6 hr) versus DMSO. Rows show Z scores
calculated for each cell type.
(B) Quartile box plots of log2 fold changes in gene expression in MYCN-amplified and nonamplified cells treated with DMSO or THZ1 at the same dose and
duration as in (A). Box plot whiskers extend to 1.5 times the interquartile range (n = 18,665 expressed genes, p < 1015 for Kelly versus SH-SY5Y and IMR-32
versus SH-SY5Y, two-sided Mann-Whitney U test).
(C) Venn diagram depicting the overlap between sets of differentially expressed transcripts (THZ1 versus DMSO) in MYCN-amplified (Kelly, IMR-32), and
nonamplified (SH-SY5Y) cells treated with THZ1 as in (A). Red represents upregulated transcripts. Blue represents downregulated transcripts.
(D) Heatmap of gene expression values of transcriptional and cell-cycle CDKs in MYCN-amplified and nonamplified cells treated with THZ1 as in (A) versus
DMSO. Rows show Z scores calculated for each cell type.
(E) Correlation between log2 fold changes in gene expression following THZ1 (100 nM) versus DMSO treatment and actinomycin D (1 mM) versus DMSO treatment
for 6 hr. in MYCN-amplified NB cells. R2 (coefficient of determination) calculated using a simple linear regression model.
See also Figure S3.decrease in CDK1 and CDK2 phosphorylation and in other pro-
teins involved in cell-cycle regulation (pRB and E2F), that was
more striking inMYCN-amplified cells (Figures 2DandS2F). How-
ever, the Pol II inhibitor triptolide appeared to show selectivity for
MYCN-overexpressing cells, compared to purvanolol, which pri-
marily targets cell-cycle CDKs (Figure S2G). Thus, although THZ1
causes cytotoxicity through transcriptional as well as cell-cycle
inhibition inMYC-driven tumor cells, the latter effect is most likely
through decreased transcription of cell-cycle CDKs.
CDK7 Inhibition Causes Widespread Transcriptional
Shutdown in MYCN-Amplified NB Cells
Because THZ1 preferentially downregulates RNA Pol II CTD
phosphorylation in MYCN-amplified cells (Figures 2A and S2A),1130 Cell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc.we next compared the consequences of CDK7 inhibition on
global gene expression in MYCN-amplified (Kelly and IMR-32)
versus nonamplified (SH-SY5Y) cells following exposure to
100 nM THZ1 for 6 hr. Expression profiling was performed with
‘‘spike-in’’ RNA standards normalized to cell number to enable
accurate detection of differences in total RNA levels in cells
with or without MYCN overexpression (Love´n et al., 2012).
We observed a genome-wide decrease in the mRNA expres-
sion levels of most actively transcribed genes inMYCN-amplified
cell lines compared toDMSO-treated cells (Figure 3A). Thiswide-
spread downregulation of gene expression was not apparent in
MYCN-nonamplified SH-SY5Y cells treated with the same
dose and duration of THZ1 (Figure 3A). Indeed, the percentage
of actively transcribed genes significantly downregulated in
these cells was only 7.5%, contrasting with 63% for Kelly and
68% for IMR-32 MYCN-amplified cells (false discovery rate
[FDR] <0.05) (Figure 3B). Moreover, Kelly and IMR-32 cells had
55% (n = 10,292) downregulated transcripts in common, while
only 12% (n = 1,225) of these were also downregulated in SH-
SY5Y cells (out of 18,665 genes) (Figure 3C). The most downre-
gulated genes and gene sets in the MYCN-amplified cells were
transcriptional and cell-cycle regulators (Figures S3A and S3B);
including transcripts of CDKs and their partner cyclins (Figures
3D andS3C). Comparison of expression profiles ofMYCN-ampli-
fied cells exposed to THZ1 with those exposed to the general
transcription inhibitor actinomycin D revealed a significant corre-
lation between the two (R2 = 0.76) (Figure 3E). These results led
us to conclude that CDK7 inhibition, through THZ1, preferentially
downregulates global transcription inMYCN-amplified NB cells,
affecting most active genes.
THZ1 Targets Deregulated MYCN in NB Cells
The selectivity of THZ1 for MYC/MYCN-deregulated cells led
us to investigate its effects on MYCN expression and function.
We observed that MYCN mRNA was among the top 15% of
significantly downregulated transcripts in NB cell lines most
sensitive to THZ1. Moreover, transcripts differentially regulated
on exposure to THZ1 showed enrichment for previously pub-
lished MYCN/MYC target gene sets (Figure S4A). THZ1 treat-
ment resulted in a dose- and time-dependent downregulation
of MYCN mRNA and protein levels in MYCN-amplified cells
(Figures 4A and 4B), which were rescued by overexpression
of the CDK7C312S mutant (Figure S4B), similar to observations
with an ATP analog in colorectal carcinoma cells expressing
a CDK7 mutation (Glover-Cutter et al., 2009). We also observed
downregulation of MYCN protein levels in the human NB tu-
mors from mice that responded to THZ1 (Figure 4C). These
effects primarily reflected a reduction in MYCN transcripts, as
comparison of MYCN protein turnover in MYCN-amplified cells
exposed to either THZ1 or actinomycin D showed largely
similar rates of degradation (Figure S4C). Finally, analysis of
MYCN occupancy at the promoters of two of its known tran-
scriptional targets, MDM2 (Slack et al., 2005) and MCL1 (La-
bisso et al., 2012), revealed significantly decreased MYCN
binding, consistent with the disruption of MYCN function by
THZ1 (Figure 4D).
Next, we determined whether genetic depletion of MYCN
mimicked the effects of THZ1 inMYCN-amplified cells. Abroga-
tion of amplified MYCN expression in Kelly cells using shRNA
knockdown led to decreased Pol II CTD phosphorylation at S2,
S5, and S7 (Figure 4E), similar to our findings with THZ1 treat-
ment. The inhibition of transcription associated with MYCN
knockdown was coupled with complete loss of MCL1 and sub-
sequent cell death (Figure 4E). We next asked whether ectopic
expression of MYCN would sensitize cells to THZ1. MYCN-
nonamplified SH-SY5Y cells were engineered to express the
oncogene by lentiviral transduction, resulting in approximately
380-fold increases inMYCNmRNAandprotein levels (Figure 4F),
equivalent to those in MYCN-amplified cells (Figure S1D).
Ectopic expression ofMYCN in these cells led to a 5-fold greater
sensitivity to THZ1 compared with untransfected or vector con-
trol-transfected SH-SY5Y cells (Figure 4G). Together, theseCresults indicate that THZ1 specifically targets deregulated
MYCN in NB cells.
Amplified MYCN Induces Global Transcriptional
Amplification that Is Inhibited by THZ1
Downregulation of MYCN alone seemed insufficient to account
for the widespread effects of THZ1 on the transcriptional output
of cells harboring amplified MYCN. We therefore questioned
whether deregulated MYCN, like MYC, binds promiscuously to
active genes, leading to global transcriptional amplification,
and whether THZ1 preferentially disrupts this effect. Indeed,
ectopic expression of MYCN in SH-SY5Y cells led to increased
cell size (Figure S5A) and significantly increased expression of
all active transcripts (Figures 5A and S5B). Moreover, THZ1
treatment led to significant downregulation of transcriptional
output in these cells (Figure 5B) with induction of apoptosis,
although MYCN protein levels were not affected (Figure 5C).
Furthermore, shRNA knockdown of MYCN in MYCN-amplified
cells led to a striking downregulation of global gene expression
in comparison to their control shRNA-expressing counterparts
(Figures 5D and 5E), again underscoring the widespread tran-
scriptional effects of deregulated MYCN. To determine the
extent to which these effects mirrored those of CDK7 inhibition,
we compared the expression profiles of MYCN-amplified cells
expressing a MYCN shRNA with those of THZ1-treated cells,
noting significant downregulation of the actively transcribed
genes in both types of cells, with a close correlation between
the top 500 downregulated transcripts in THZ1-treated cells
and those in MYCN shRNA-depleted cells (Figures 5F and
S5C). Hence, disruption ofMYCN-induced transcriptional ampli-
fication also contributes to the striking effects of THZ1.
Super-Enhancers Account for the Selectivity of THZ1
forMYCN-Amplified NB Cells
Weobserved that the ectopic overexpression ofMYCN in nonam-
plified cells led to global transcriptional upregulation and sensiti-
zation to the growth inhibitory effects of THZ1, although the latter
effect did not approach the levels seen in cells with endogenously
amplified MYCN. We therefore investigated the possible contri-
bution of super-enhancers (SEs) to the extreme susceptibility of
endogenous MYCN-amplified cells to THZ1. Using chromatin
immunoprecipitation with high-throughput sequencing (ChIP-
seq) of histone H3K27 acetylation (H3K27ac), a mark of active
enhancers (Hnisz et al., 2013), we first identified enhancer regions
in MYCN-amplified Kelly and nonamplified SH-SY5Y cells (Fig-
ure S6A). In both cell types, a subset of H3K27ac-bound en-
hancers (Kelly 6.1%, SH-SY5Y, 5.4%) had a significantly higher
signal than regular enhancers and were therefore classified
as SEs (Love´n et al., 2013; Whyte et al., 2013) (Figure 6A). We
also analyzed the occupancy of H3K4 monomethylation, a mark
that colocalizes with H3K27ac in strong enhancers, noting a
high concordance (94%–99%) with enhancers identified by
H3K27ac analysis (Figures 6B and S6B).
The SEs in MYCN-amplified cells were either unique or dis-
proportionately loaded with H3K27ac, with the largest SE being
associated with the MYCN oncogene itself, having an H3K27Ac
signal that was at least ten times greater than that of any other SE
in either these orMYCN-nonamplified cells (Figures 6A and 6B).ell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc. 1131
Figure 4. Cytotoxic Effects of THZ1 Are Mediated in Part through Inhibition of MYCN Expression
(A) Quantitative RT-PCR (qRT-PCR) analysis ofMYCNRNA expression inMYCN-amplified Kelly cells treated with THZ1 50 nM for 0–6 hr (left) or 0–250 nM for 6 hr
(right). Data normalized to b-actin are presented as mean ± SD of three biological replicates.
(B) Immunoblot analysis of MYCN protein expression in MYCN-amplified NB cells treated with the indicated doses of THZ1 for 6 or 24 hr.
(C) IHC analysis of MYCN protein expression inMYCN-amplified human NB xenograft models treated with either DMSO or 10 mg/kg i.v. twice daily of THZ1 for
12 days. Scale bars represent 25 mM.
(D) ChIP-qPCR analysis of MYCN binding at the promoters of candidate target genes in MYCN-amplified cells following treatment with THZ1, 100 nM for 3 hr.
Mean ± SD values for three replicate experiments are shown. **p < 0.01 (Student’s t test).
(E) Immunoblot analysis of the indicated proteins inMYCN-amplified NB cells expressing either an shRNA control (shGFP) or an shRNA directed againstMYCN
(shMYCN). Two different hairpins against MYCN [shMYCN(1) and shMYCN(3)] were used with similar results.
(F) qRT-PCR analysis ofMYCN expression in SH-SY5YMYCN-nonamplified cells engineered to express either a control vector (pLenti 6.3) orMYCN (pLenti 6.3-
MYCN (left). Immunoblot analysis of MYCN protein expression in these cells (right).
(G) Cell viability analysis of untransfected (SH-SY5Y), control vector-expressing (pLenti 6.3) or MYCN-expressing (pLenti 6.3-MYCN) MYCN-nonamplified NB
cells treated for 72 hr with increasing doses of THZ1. Results are means ± SD of three replicates.
See also Figure S4.Because the MYCN SE in Kelly cells is contained within the
MYCN amplicon, we questioned whether its SE status merely re-
flected the increased number of copies of the amplified gene. To
investigate this possibility, we estimated the signal of a single1132 Cell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc.copy of MYCN and recalculated its rank within the list of en-
hancers. A single copy of the MYCN enhancer still fell within
the group of SEs (ranked 250 out of 746), indicating that
increased gene copy number does not account for the high SE
Figure 5. THZ1 Inhibits MYCN-Driven Transcriptional Amplification
(A) Box plot depicting the log2 fold changes in actively transcribed genes in
MYCN-nonamplified SH-SY5Y cells transduced with MYCN (pLenti 6.3-
MYCN) compared with a control vector (pLenti 6.3). Box plot whiskers extend
to 1.5 times the interquartile range (n = 18,665 expressed genes; p < 2.2 3
1016, two-sided Mann-Whitney U test).
Csignal associated withMYCN. The majority of genes associated
with the remaining top-ranked SEs were master transcription
factors critical to sympathetic neuronal development and cell
identity including PHOX2B (Pattyn et al., 1999; Stanke et al.,
1999), GATA2 (Tsarovina et al., 2004), HAND2 (Howard et al.,
2000), and DBH (Mercer et al., 1991) (Figures 6A and 6C).
Another major oncogenic driver in NB, the receptor tyrosine ki-
nase ALK (George et al., 2008), was associated with a unique
top-ranked SE in MYCN-amplified cells (Figures 6A and 6C). In
general, the SE domains associated with MYCN amplification
correlated with pathways involved in the regulation of transcrip-
tion, while those in nonamplified cells were primarily related to
cell adhesion, invasion, metastasis and receptor tyrosine kinase
pathways (Figures 6D and S6C). To ensure that the SEs in the
cultured cells mirrored those of human NB, we analyzed
H3K27ac occupancy in three primary tumors (Figures 6E and
S6D). Consistent with our cell line data, the largest SE in
MYCN-amplified samples NB#1 and NB#2 was associated
withMYCN (Figures 6E and S6E). SEs associated with PHOX2B
and HAND2 were identified in all tumor samples (Figure 6E), in
keeping with their lineage-specific role in sympathetic neuronal
development.
To determine whether the occurrence of SEs correlates with
increased Pol II occupancy, we used ChIP-seq analysis of Pol
II and observed that the proximal promoter regions of SE-asso-
ciated genes had higher levels of Pol II occupancy compared
with regular enhancers in both MYCN-amplified and nonampli-
fied cells, although the difference was much more striking in
the former (Figure 7A). THZ1 treatment led to a striking reduction
in Pol II binding at the promoter regions and gene bodies of SE-
associated genes inMYCN-amplified but not nonamplified cells
(Figure 7A). Pol II binding at regular enhancer-associated genes
was not appreciably affected by THZ1 in either cell type (Fig-
ure 7A). The reduction in Pol II occupancy with THZ1 was
observed at the transcription start and end sites of genes asso-
ciated with the top-ranked SEs, including MYCN, suggesting
that their expression was severely curtailed in these cells (Fig-
ure 7B). Indeed, RNA expression of SE-associated genes was
significantly reduced after THZ1 treatment in MYCN-amplified
cells (Figure 7C) but not of the same genes in MYCN-nonampli-
fied cells (Figure 7C). Thus, not only do SEs in MYCN-amplified(B) Heatmap of all gene expression values in MYCN-nonamplified SH-SY5Y
cells versus SH-SY5Y cells overexpressing MYCN (pLenti 6.3-MYCN)
following either THZ1 (100 nM for 6 hr) or DMSO treatment. Rows show Z
scores calculated for each vector.
(C) Immunoblot analysis of MYCN, CC3, and cleaved PARP in SH-SY5Y
MYCN-nonamplified cells engineered to express either a control vector (pLenti
6.3) or MYCN (pLenti 6.3-MYCN) following treatment with THZ1.
(D) Heatmap of differentially expressed genes in MYCN-amplified NB cells
expressing a MYCN shRNA versus control shRNA. Rows show Z scores
calculated for each vector.
(E) Box plots of log2 fold changes in gene expression in MYCN-amplified NB
cells expressing a MYCN shRNA versus a control shRNA. Box plot whiskers
extend to 1.5 times the interquartile range (n = 18,665 expressed genes; p <
1015 for shMYCN versus shGFP, two-sided Mann-Whitney U test).
(F) GSEA plot depicting the correlation between the top 500 downregulated
genes following THZ1 treatment and the rank-ordered genes that are differ-
entially expressed after MYCN knockdown in MYCN-amplified NB cells.
See also Figure S5.
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Figure 6. NB Cells Possess Unique Super-Enhancer Landscapes
(A) H3K27ac signal across enhancer regions for all enhancers in MYCN-amplified and nonamplified cells. SEs were defined as enhancers surpassing the
threshold signal of 8,802 in both cell types. In Kelly and SH-SY5Y cells, 6.1% (746/12,200) and 5.4% (1,136/20,887) of the enhancers comprised 52% and 37%,
respectively of all H3K27ac-bound enhancer signal and were classed as SEs.
(B) ChIP-seq profiles for H3K27ac, H3K4me1, and RNA Pol II binding at theMYCN SE gene locus in Kelly cells. The x axis shows genomic position and the y axis
the signal of histone mark or Pol II binding in units of reads per million per base pair (rpm/bp). The genemodel is depicted below and scale bars above the binding
profiles.
(C) ChIP-seq profiles for H3K27ac binding at representative SE-associated gene loci in MYCN-amplified and nonamplified cells. The x and y axes are as
described in (B).
(D) GeneOntology (GO)molecular functions of SE-associated genes inMYCN-amplified (Kelly) and nonamplified (SH-SY5Y) cells identified usingGREAT analysis
(McLean et al., 2010).
(E) H3K27ac loading across enhancers inMYCN-amplified and nonamplified primary NB tumors. SEs were defined as having a threshold signal of 2,427 (NB#1),
5,933 (NB#2), and 5,952 (NB#3). In NB#1 and NB#2, 8.5% (164/1,920) and 3.0% (109/3,561), and in NB#3, 6.4% (522/8,040) of the enhancers were classified
as SEs.
See also Figure S6.
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Figure 7. Sensitivity of MYCN-Amplified Cells to THZ1 Correlates with MYCN-Associated Super-Enhancers
(A) Metagene representation of global Pol II ChIP-seq occupancy at SE- and RE-associated genes in cells with (Kelly) or without (SH-SY5Y)MYCN amplification
treated with DMSO (blue) or THZ1 (red) (100 nM 3 3 hr). TSS, transcription start sites.
(B) Gene tracks of RNA Pol II binding density at representative SE-associated gene loci after DMSO or THZ1 treatment as in (A).
(C) Left: quartile box plots of log2 fold changes in the top 231 genes associated with SEs and regular enhancers (RE) inMYCN-amplified cells treated with THZ1
(100 nM3 6 hr) versus DMSO. Box plot whiskers extend to 1.5 times the interquartile range (n = 230 SE; n = 231 RE; p < 102, two-sided Mann-Whitney U test).
Right: quartile box plots of log2 fold changes in gene transcripts associated with the top-ranked SEs unique toMYCN-amplified Kelly cells treated with THZ1 as in
(A) versus DMSO, compared with the expression changes of the same genes in similarly treated SH-SY5Y nonamplified cells. Box plot whiskers extend to 1.5
times the interquartile range (n = 673; p < 1016, two-sided Mann-Whitney U test).
(D) Proposed mechanism for the action of THZ1 inMYCN-amplified NB. OncogenicMYCN is regulated by super-enhancers leading to its high-level expression
(left). OverexpressedMYCN invades the promoter and enhancer regions of all active genes, including itself, to induce global transcriptional upregulation (right).
THZ1 targets the expression of both MYCN and MYCN-driven transcriptional amplification.
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cells cause high-level expression of oncogenic drivers and
genes that determine cell identity, but they also provide the basis
for the selectivity of THZ1.
DISCUSSION
Here, we demonstrate that the genomically amplified MYCN
oncogene, by promoting the development of SEs, causes upre-
gulation of the active transcriptional program of NB cells, sensi-
tizing them to inhibition of CDK7, a widely expressed regulator of
transcription and cell-cycle transition. This effect suppresses
essentially all active transcripts, especially those responsible
for the uncontrolled proliferation that characterizes the cancer
cell state, leading to potent and selective cytotoxicity while
sparing normal cells. The high potency of our CDK7 inhibitor,
THZ1, can be explained in part by its unprecedented mode of
binding—the formation of a covalent bondwith a unique cysteine
residue outside the kinase domain—resulting in prolonged and
irreversible CDK7 inactivation (Kwiatkowski et al., 2014). This
feature contrasts with other transcriptional CDK inhibitors,
including flavopiridol, roscovitine and CR-8 (Table S1), all of
which rely on ATP-competitive modes of binding and whose ef-
fects on transcription would therefore be expected to be tran-
sient. The selectivity of THZ1 for MYCN-amplified cells can be
attributed to the perturbation of SEs associatedwith deregulated
MYCN and other oncogenic drivers.
Despite risk-based treatment strategies for MYCN-amplified
NB, responses tend to be brief, with early relapses that are
almost uniformly fatal (Matthay et al., 1999). Finding suitable
ways to inhibit MYCN, or any MYC family member for that
matter, has been notoriously difficult. A recent approach is the
modulation of bromodomain and extraterminal (BET) domain
coactivator proteins, such as BRD4, which associate with acet-
ylated chromatin and promote transcriptional activation (Del-
more et al., 2011; Love´n et al., 2013; Puissant et al., 2013). After
successful testing of the BRD4 inhibitor JQ1 in MYC-dependent
multiple myeloma models (Delmore et al., 2011), a positive cor-
relation between MYCN amplification and sensitivity to JQ1
was demonstrated in themajority ofMYCN-amplified NBmodels
tested (Puissant et al., 2013). However, others reported growth
inhibition of NB using the structurally distinct BRD4 inhibitor
I-BET726, irrespective of MYCN amplification status or MYC/
MYCN expression levels (Wyce et al., 2013). The intervention
we describe has a number of features that would support the
clinical development of covalent CDK7 inhibitors for use against
MYCN-amplified NB and other MYC-driven cancers. These
include the ability to achieve potent growth inhibition with rela-
tively low doses of THZ1, the lack of off-target effects, and the
absence of discernible toxicity in a mouse model of NB. THZ1
has been demonstrated to cross-react with CDK12/13 (Kwiat-
kowski et al., 2014); however, shRNA knockdown of these
kinases inMYCN-amplified cells did not affect MYCN levels (Fig-
ure S1B). Furthermore, overexpression of CDK7C312S restored
MYCN levels to near amplified levels (Figure S4B). These results
would suggest that loss of CDK7 activity dominates the selective
effects of THZ1 in MYCN-amplified NB cells.
Multiple studies argue that MYC is a global transcriptional
amplifier (Lin et al., 2012; Love´n et al., 2012; Nie et al., 2012;1136 Cell 159, 1126–1139, November 20, 2014 ª2014 Elsevier Inc.Schuhmacher and Eick, 2013), although a recent report has sug-
gested that a portion of this amplification is indirect (Sabo` et al.,
2014). We believe the transcriptional amplification effects of
MYC are direct at the vast majority of active genes and that dif-
ferences in interpretation of direct versus indirect effects are due
to differences in interpretation of ChIP-seq data thresholds. We
demonstrate here that deregulated MYCN functions as a tran-
scriptional amplifier of the cell’s existing gene expression pro-
gram rather than a specific target gene set. This effect was not
detectable in earlier data sets ofMYCN-amplified tumor samples
because of a limitation of microarray analysis, which in conven-
tional approaches assumes similar levels of total RNA in all the
samples (Love´n et al., 2012).
Although in principle, blockade of CDK7 function would be ex-
pected to inhibit the expression of any gene poised to undergo
transcription, our direct demonstration that manipulation of
MYCN levels can modulate the sensitivity to THZ1 supports
the idea thatMYC-induced transcriptional amplification is crucial
to THZ1 activity. This transcriptional dependency was illustrated
by the massive transcriptional shutdown in MYCN-amplified
cells with relatively low doses of THZ1 (Figure 3). By contrast,
although CDK transcripts were downregulated by THZ1 in
MYCN-nonamplified cells, this effect did not produce the same
profound impact seen inMYCN-amplified cells, providing further
evidence that aberrant MYCN expression and the resultant
global amplification of transcription are necessary for cell
sensitivity to THZ1. This critical dependency on transcriptional
amplification would account for the selective killing of MYCN-
amplified cells by THZ1 without inducing toxic side effects in
mice. The unique SE landscapes of MYCN-amplified cells also
dictate their response to THZ1. Indeed, genes involved in the
oncogenic state—such as MYCN and ALK, and those that
specify sympathetic neuronal cell identity including PHOX2B
and HAND2—were associated with SEs and were far more sus-
ceptible to THZ1 than either their counterparts inMYCN-nonam-
plified cells or genes driven by regular enhancers. This selectivity
of THZ1 for MYCN-amplified cells could stem from its inhibition
of the increased Pol II activity at SE-associated genes, leading to
downregulation ofMYCN expression as well as that of the entire
transcriptional program of the cell.
Our data suggest that the cytotoxicity induced by THZ1 in
MYCN-driven NB cells is mediated by inhibition of both MYCN
expression and MYCN-stimulated global transcriptional ampli-
fication (Figure 7D). Oncogenic MYCN invades the core pro-
moters and enhancer regions of actively transcribed genes,
resulting in the formation of SEs at key genes underlying the can-
cer cell state, including MYCN, and ultimately in transcriptional
amplification. THZ1, by irreversibly inhibiting CDK7, blocks tran-
scription of MYCN (Figure 4) as well as MYCN-induced amplifi-
cation of global gene transcription. The latter conclusion is
based on the widespread inhibition of transcription in MYCN-
amplified cells (Figure 3), the highly significant correlation be-
tween the transcripts that were downregulated by THZ1 and
those resulting from genetic depletion of MYCN, and the fact
that ectopic expression ofMYCN in non-MYCN-overexpressing
cells sensitizes these cells to widespread transcriptional inhibi-
tion by THZ1 (Figures 4 and 5). Together, these two processes
effectively deprive tumor cells of the proliferative signals to which
they have become addicted, leading to apoptotic death. Never-
theless, this mechanism is not necessarily specific to deregu-
lated MYCN or MYC. Rather, we suggest that inhibition of
CDK7 or perhaps other transcriptional CDKs would be effective
in any context in which tumor cells rely on high-level expression
of one or more oncogenic transcription factors for their aberrant
growth and survival. However, the net inhibitory effect is likely to
be much more profound in cancers that depend on MYC (or
MYCN) as the oncogenic driver.
In conclusion, we use NB and a newly developed transcrip-
tional CDK inhibitor to demonstrate the potency and selectivity
of a potential treatment strategy that targets global transcrip-
tional amplification in MYC-driven tumors. Our results suggest
that the mechanism by which oncogenic MYC gains control
over myriad cellular processes to induce tumor formation also
exposes a vulnerability that can be exploited therapeutically.
By using THZ1 to disable essential components of the cancer
cells’ transcriptional machinery, we show that widespread sup-
pression of transcription in MYC-dependent cancers is not
only feasible, but also spares normal cells from toxicity.
EXPERIMENTAL PROCEDURES
Cell Lines
Human NB cell lines (from the Children’s Oncology Group) and Raji and Daudi
cells (provided by D. Sabatini, Massachusetts Institute of Technology) were
grown in RPMI-1640, 10% fetal bovine serum (FBS), and 1% penicillin/strep-
tomycin (pen/strep; Invitrogen). H262-BT111 primitive neuroectodermal tumor
cells (provided by K. Ligon, Dana-Farber Cancer Institute [DFCI]) were grown in
neuronal stem cell (NSC) media with heparin, NSC supplement (Stem Cell
Technologies), 1% pen/strep, erythrocyte growth factor (EMD Millipore), and
fibroblast growth factor (Life Technologies). NIH 3T3 cells (purchased from
ATCC) and B6-MEFs (provided by A. Kung, Columbia University) were grown
in DMEM with 10% FBS and 1% pen/strep.
Animal Studies
These experiments were performed with approval from the Institutional Animal
Care and Use Committee of the DFCI. Full details are given in Extended Exper-
imental Procedures.
Synthetic RNA Spike-In and Microarray Analysis
RNA sampleswere prepared as previously described (Love´n et al., 2012). Total
RNA was spiked-in with RNA Spike-In Mix (Ambion), treated with DNA-free
DNase I (Ambion), analyzed on Agilent 2100Bioanalyzer (Agilent Technologies)
for integrity, and hybridized to Affymetrix GeneChip PrimeView Human Gene
Expression arrays (Affymetrix). Data analysis is described in Extended Exper-
imental Procedures.
ChIP-Seq
ChIP was carried out as previously described (Lee et al., 2006) with minor
changes described in the Extended Experimental Procedures. The following
antibodies were used: RNAPII (Santa Cruz, sc-899), H3K4me1 (Abcam,
ab8895), and H3K27ac (Abcam, ab4729).
Data Analysis
All ChIP-seq data were aligned using the short-read aligner Bowtie (version
0.12.7) (Langmead et al., 2009) to build version GRCh37/HG19 of the human
genome. To visualize ChIP-seq tracks, reads were extended by 160 bases,
converted into tdf files using igvtools (version 2.2.1) and visualized in IGV (Rob-
inson et al., 2011). ChIP-seq peaks were detected using a peak-finding algo-
rithm, MACS version 1.4.2 (Zhang et al., 2008) with the default p value
threshold of enrichment of 1 3 105 used for all data sets. Active enhancers,
ranked according to the magnitude of the H3K27ac signal, were defined as re-Cgions of ChIP-seq enrichment for H3K27ac and H3K4me1 outside of pro-
moters. To identify super-enhancers, we employed the ROSE algorithm
(https://bitbucket.org/young_computation/rose) (Love´n et al., 2013; Whyte
et al., 2013) to rank the enhancers that were identified using MACS in which
peaks within 12.5 kb of one another were stitched together and these stitched
enhancers were ranked by their difference in H3K27ac signal versus input
signal. Further details are given in the Extended Experimental Procedures.
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